PATENT CLAIM ANALYSIS

Application Number: 15944332
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "489000"]

Abstract:
The present invention provides a sustained release formulation of an active pharmaceutical ingredient (“API”). In particular, the sustained release formulation is adapted for topical administration or administration via injection and comprises a nanoemulsion of oil-in-water. In some embodiments, the API is an ophthalmic API. The present invention also provides a method for treating an eye disorder using a sustained release formulation. In one particular embodiment, the invention provides methods for treating dry eye syndrome using a sustained release formulation comprising a nanoemulsion of oil-in-water and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof.

Claim (Index 15):
The method of  claim 14 , wherein the ADDE is Sjogren dry eye syndrome, ocular Graft-Versus-Host-Disease (oGVHD) or non-Sjogren dry eye syndrome.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 91.0
- Lexical Diversity: 1.86441
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15051654', '15464290', '15676968', '12501316', '15279301']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7721027078851264
- 35 USC 102 Novelty (BERT): 0.5550602578625768
- Combined Prediction Score: 0.7503984628828715
- Mean Citation Score: 327.63336
- Max Citation Score: 441.6487
- Similarity Product: 318.30575877949

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test